Reviews | Why is Makena staying on the market?
In late October, an FDA advisory committee voted forcefully against continuing FDA approval of 17α-hydroxyprogesterone caproate (17-OHPC; Makena), a drug indicated to reduce the risk of preterm labor in pregnant women. In documents prepared by FDA scientists ahead of the committee hearing, the conclusion was that the drug “should be taken off the market.” Similarly, …